Elite dna therapy services naples
31, male, useless ancient Psych BA, trying to figure out how to get ANY decent job...
2023.03.20 16:47 BeanLordUltra 31, male, useless ancient Psych BA, trying to figure out how to get ANY decent job...
My main issue, is I spent my 20's working at a grocery chain. I didn't do well enough for grad school, kind of fell out of wanting to go into counseling, and figured I could manage a store and make life work. Then covid happened, I injured my back due to poorly built pallets from the warehouse and overwork. I only got 6 months of WC and couldn't take legal recourse.
Since, I just got seasonal jobs at parks but my body can't take it anymore. I look at miscellaneous office jobs on indeed, and the fact that I have no real office experience or experience in any specific industry over the past 10 years and no real career are driving me to suicidal ideation. I currently work for the government, but don't get health insurance for another 6 months so therapy isn't an option right now. I was in therapy for 8 years however, that came to a mutual end last year. I also make less than $20/hr in a HCOL area, and thus currently live with a parent.
I toyed with going back to school for what I'd truly enjoy doing, but I don't have money and student loan payments return very soon, and I still owe for my Bachelors. I'm not sure what my options are. I'd be willing to train for something, if feasible. I am not attuned to learning how to code, but am technologically adept. My only skills at this point are the 10 years of customer service/being a section leader and horticulture/landscaping.
I just need something. I can't move out of home. I can't date. I don't see my friends because of the shame I feel with where I am in life compared to everyone else who just sucked it up, worked hard and accepted that they'd have to work a job they didn't like to pay for the ability to live freely.
I know I am not in the healthiest place mentally, but my body can't take much more of my current job and the 2 hours of driving a day I have to do to get there are things I need to remedy quickly. I'm just so lost.
submitted by BeanLordUltra to findapath [link] [comments]
Since, I just got seasonal jobs at parks but my body can't take it anymore. I look at miscellaneous office jobs on indeed, and the fact that I have no real office experience or experience in any specific industry over the past 10 years and no real career are driving me to suicidal ideation. I currently work for the government, but don't get health insurance for another 6 months so therapy isn't an option right now. I was in therapy for 8 years however, that came to a mutual end last year. I also make less than $20/hr in a HCOL area, and thus currently live with a parent.
I toyed with going back to school for what I'd truly enjoy doing, but I don't have money and student loan payments return very soon, and I still owe for my Bachelors. I'm not sure what my options are. I'd be willing to train for something, if feasible. I am not attuned to learning how to code, but am technologically adept. My only skills at this point are the 10 years of customer service/being a section leader and horticulture/landscaping.
I just need something. I can't move out of home. I can't date. I don't see my friends because of the shame I feel with where I am in life compared to everyone else who just sucked it up, worked hard and accepted that they'd have to work a job they didn't like to pay for the ability to live freely.
I know I am not in the healthiest place mentally, but my body can't take much more of my current job and the 2 hours of driving a day I have to do to get there are things I need to remedy quickly. I'm just so lost.
2023.03.20 16:35 ofotinlondon Big dilemma for me about being a small shop owner in Central London. Feedbacks appreciated.
Hello dear Reddit users.
I briefly would like to explain my background then ask your opinion about my next big career move.
I’m a 28 years old Turkish national and I’ve been residing in The UK, London since 2016. I’ve been running my small business in digital marketing and I survive, pay my tax, rent and bills. Sometimes getting support from my family from Istanbul when needed.(covid and brexit hit me hard sadly). I need to emphasise that I’m not happy with the work I do and I need a change.
Everyone in my big family are business owners. From my uncles to grandparents, aunts to my own parents. I’ve grown up seeing them doing their own works, managing their own shops, showrooms etc. I’ve also done my own work in digital marketing and e commerce services in the Uk but it was more of an obligation for me as I’ve lived in the Uk with Turkish businessperson visa which did not allow me to work for a company. I’ve done my masters in finance in a Russel group university and always educated myself(coding and testing). Have waited this time for years and now I have ILR. Basically free to do any work. No more Home Office or immigration control.
I’ve been applying for entry level jobs. Though, it’s so tough and the situation is desperate for me. For such small amounts -not overlooking the salaries, just based on what I make currently and checking my expenses, and comparing wages to what my dad makes-, companies reject my applications. For example, I can’t pass interviews for a job pays £30k PA before tax. The problem here is possibly me because I’ve never ever had a corporate experience or took an interview before. I always convinced my own customers for projects. And another bad part of me is, having almost zero knowledge about corporate life English. I believe that my English is more than ok, about IELTS 7 level, however, I also believe that the corporate English skills of mine won’t get any better.
This whole situation makes me feel slightly depressed and overwhelmed in the last few months. The reality is, even if everything goes 10/10, within 5-8 years my salary will be £70-90k in fintech, and I’ll be making anywhere between £4-5k per month after tax. Taking account that I live with my sister and we rent two bedrooms in zone 2, the rent including bill is about £3k, this wage seem so low to me. Remember this is the best scenario and I’d be able to reach these figures at least in a few years.
I’ve been thinking of other work alternatives and seriously considering being a small shop owner in central london focusing on selling silver jewelleries. From age 12 to 18, I spent my summer holidays in grand bazaar, old town Istanbul and worked for jewellers sometimes in showrooms and sometimes in ateliers. I don’t say I know the industry well because I was a kid during all those times, but I feel quite close to the idea as I’m familiar with most of the things and dynamics. I believe that I have developed my interpersonal skills exceptionally at those times, and I benefited that quite a lot in the UK. I was told at that I’ve got a charming side and good at convincing people.
As well as all these, my dad, he’s a car dealer and showroom runner with my uncle, has also have a business partnership with an atelier and they import fine jewelleries to few countries in Europe and Middle East. Because of his connection and my good relation with the atelier guy, he’s ok to do any favour for me for the new idea, like supplying for my shop or finding the best suppliers, he says.
Apart from all these, my dad supports me for this idea more than anything I did in my entire life because he always wanted me to be a proper businessman. He always politely judged me wanting to be in corporate life, now when I go to him with the idea, he opens the doors, encourages and supports me either financially or thru his contacts in grand bazaar. However, because of my relationship with my parents, I’ve always hesitated to make a mistake until today and never been a risk taking person. I’ve always been conservative with my life. It’s an issue of a therapy in my opinion and the idea of failing with this business after all those supports(potentially over £100k), makes me feel sick. He and my uncle tell me don’t start doing anything with such pessimistic ideas or you’ll surely fail. They’re probably right. I guess I need to sort out my own mind issues before everything. Though I’m closer to the idea and being brave to move more than a month ago after having hours of conversations with my dad, mum and uncle.
So I kindly would like to ask you what should I do and how should I move.
They tell me if you’re going for it, go for the best one. We’ve got an idiom. If you’ll die, die in the biggest sea. Therefore I’m considering a shop in west end. More particularly Covent Garden, nearby seven dials market. I’d like to focus on modern and trendy looking silver made jewelleries which will make the prices affordable for almost any women either local or tourist.
Some roughly estimated figures about the idea.
-Annual rent of the shop will be at least £50k and could go to anywhere nearby £70-80k. Other costs related to rent? I’ve got no idea. I’ll start talking to agencies this week as I’m abroad at the moment.
-cost of goods... 0.72$ is the price for a gram of silver. Any piece from ear rings to bracelets may vary from 2 gram to 20-30gram. Labour will be about 4$ per gram for me. No idea how much inventory stocks I have to have.
-other small things like interior design including the display, other inventory stocks apart from goods etc. I see these are going to £15-20k. Though I’ve got no real idea and this range is just my guess.
Overall, I can clearly see about £100k going for a business like this very quickly but I can’t estimate the potential sales and turnovers. It’s so difficult to spot this for me. There are 4-5 main competitors in the area, there’s no need to mention their names. This gives me some hopes but again, no proper estimation or forecast…
Looking forward to hearing back from like minded people and open for suggestions. Desperately need feedbacks from people.
Thank you!
submitted by ofotinlondon to UKJobs [link] [comments]
I briefly would like to explain my background then ask your opinion about my next big career move.
I’m a 28 years old Turkish national and I’ve been residing in The UK, London since 2016. I’ve been running my small business in digital marketing and I survive, pay my tax, rent and bills. Sometimes getting support from my family from Istanbul when needed.(covid and brexit hit me hard sadly). I need to emphasise that I’m not happy with the work I do and I need a change.
Everyone in my big family are business owners. From my uncles to grandparents, aunts to my own parents. I’ve grown up seeing them doing their own works, managing their own shops, showrooms etc. I’ve also done my own work in digital marketing and e commerce services in the Uk but it was more of an obligation for me as I’ve lived in the Uk with Turkish businessperson visa which did not allow me to work for a company. I’ve done my masters in finance in a Russel group university and always educated myself(coding and testing). Have waited this time for years and now I have ILR. Basically free to do any work. No more Home Office or immigration control.
I’ve been applying for entry level jobs. Though, it’s so tough and the situation is desperate for me. For such small amounts -not overlooking the salaries, just based on what I make currently and checking my expenses, and comparing wages to what my dad makes-, companies reject my applications. For example, I can’t pass interviews for a job pays £30k PA before tax. The problem here is possibly me because I’ve never ever had a corporate experience or took an interview before. I always convinced my own customers for projects. And another bad part of me is, having almost zero knowledge about corporate life English. I believe that my English is more than ok, about IELTS 7 level, however, I also believe that the corporate English skills of mine won’t get any better.
This whole situation makes me feel slightly depressed and overwhelmed in the last few months. The reality is, even if everything goes 10/10, within 5-8 years my salary will be £70-90k in fintech, and I’ll be making anywhere between £4-5k per month after tax. Taking account that I live with my sister and we rent two bedrooms in zone 2, the rent including bill is about £3k, this wage seem so low to me. Remember this is the best scenario and I’d be able to reach these figures at least in a few years.
I’ve been thinking of other work alternatives and seriously considering being a small shop owner in central london focusing on selling silver jewelleries. From age 12 to 18, I spent my summer holidays in grand bazaar, old town Istanbul and worked for jewellers sometimes in showrooms and sometimes in ateliers. I don’t say I know the industry well because I was a kid during all those times, but I feel quite close to the idea as I’m familiar with most of the things and dynamics. I believe that I have developed my interpersonal skills exceptionally at those times, and I benefited that quite a lot in the UK. I was told at that I’ve got a charming side and good at convincing people.
As well as all these, my dad, he’s a car dealer and showroom runner with my uncle, has also have a business partnership with an atelier and they import fine jewelleries to few countries in Europe and Middle East. Because of his connection and my good relation with the atelier guy, he’s ok to do any favour for me for the new idea, like supplying for my shop or finding the best suppliers, he says.
Apart from all these, my dad supports me for this idea more than anything I did in my entire life because he always wanted me to be a proper businessman. He always politely judged me wanting to be in corporate life, now when I go to him with the idea, he opens the doors, encourages and supports me either financially or thru his contacts in grand bazaar. However, because of my relationship with my parents, I’ve always hesitated to make a mistake until today and never been a risk taking person. I’ve always been conservative with my life. It’s an issue of a therapy in my opinion and the idea of failing with this business after all those supports(potentially over £100k), makes me feel sick. He and my uncle tell me don’t start doing anything with such pessimistic ideas or you’ll surely fail. They’re probably right. I guess I need to sort out my own mind issues before everything. Though I’m closer to the idea and being brave to move more than a month ago after having hours of conversations with my dad, mum and uncle.
So I kindly would like to ask you what should I do and how should I move.
They tell me if you’re going for it, go for the best one. We’ve got an idiom. If you’ll die, die in the biggest sea. Therefore I’m considering a shop in west end. More particularly Covent Garden, nearby seven dials market. I’d like to focus on modern and trendy looking silver made jewelleries which will make the prices affordable for almost any women either local or tourist.
Some roughly estimated figures about the idea.
-Annual rent of the shop will be at least £50k and could go to anywhere nearby £70-80k. Other costs related to rent? I’ve got no idea. I’ll start talking to agencies this week as I’m abroad at the moment.
-cost of goods... 0.72$ is the price for a gram of silver. Any piece from ear rings to bracelets may vary from 2 gram to 20-30gram. Labour will be about 4$ per gram for me. No idea how much inventory stocks I have to have.
-other small things like interior design including the display, other inventory stocks apart from goods etc. I see these are going to £15-20k. Though I’ve got no real idea and this range is just my guess.
Overall, I can clearly see about £100k going for a business like this very quickly but I can’t estimate the potential sales and turnovers. It’s so difficult to spot this for me. There are 4-5 main competitors in the area, there’s no need to mention their names. This gives me some hopes but again, no proper estimation or forecast…
Looking forward to hearing back from like minded people and open for suggestions. Desperately need feedbacks from people.
Thank you!
2023.03.20 16:19 SchlesingerMindy323 [HIRING] 25 Jobs in KY Hiring Now!
2023.03.20 16:12 Mwolf1 I asked AI to give me 100 things it couldn't do that humans could do from the perspective of selling paid services. Here's what it told me.
- Provide a personal touch in customer service
- Interpret human emotions and tone of voice accurately
- Read nonverbal cues and body language
- Form personal connections and relationships with clients
- Offer genuine empathy and compassion
- Provide in-person consultations or meetings
- Offer physical demonstrations or product samples
- Shake hands and make eye contact
- Attend events and network on behalf of a business
- Provide live entertainment or performance
- Create handcrafted products
- Offer physical assistance or manual labor
- Provide personal security or bodyguard services
- Offer professional photography or videography services
- Offer personalized shopping experiences
- Offer personal styling and fashion advice
- Provide personal training or coaching
- Offer motivational speeches or keynote presentations
- Provide physical therapy or massage services
- Offer landscaping or gardening services
- Offer home cleaning or organization services
- Provide pet care services
- Offer babysitting or childcare services
- Provide tutoring or educational services
- Offer art or music lessons
- Offer cooking or catering services
- Provide event planning or coordination services
- Offer interior design or home renovation services
- Provide legal or financial advice
- Offer counseling or therapy services
- Provide medical diagnosis or treatment
- Offer spiritual guidance or pastoral care
- Provide hair and beauty services
- Offer driving or transportation services
- Provide housekeeping or cleaning services for a business
- Offer security guard or patrol services for a business
- Provide on-site technical support or IT services
- Offer delivery or courier services
- Provide live translation or interpretation services
- Offer courtroom representation or legal advocacy
- Provide wildlife or nature tours
- Offer travel planning or booking services
- Provide tour guide services
- Offer language lessons or translation services
- Provide construction or renovation services
- Offer home inspection or appraisal services
- Provide automotive repair or maintenance services
- Offer financial planning or investment services
- Provide insurance or risk management services
- Offer marketing or advertising services
- Provide public relations or media relations services
- Offer event marketing or promotion services
- Provide graphic design or branding services
- Offer web design or development services
- Provide copywriting or content creation services
- Offer social media management or advertising services
- Provide SEO or SEM services
- Offer pay-per-click advertising services
- Provide email marketing or automation services
- Offer video production or animation services
- Provide podcast production or editing services
- Offer music production or recording services
- Provide sound design or audio editing services
- Offer voiceover or narration services
- Provide live sound engineering or mixing services
- Offer DJ or music performance services
- Provide event lighting or production services
- Offer stage management or production services
- Provide event ticketing or registration services
- Offer event sponsorship or fundraising services
- Provide catering or food and beverage services for an event
- Offer event décor or rental services
- Provide event security or crowd management services
- Offer event transportation or parking services
- Provide event photography or videography services
- Offer event planning or coordination services for a nonprofit organization
- Provide volunteer coordination or management services for a nonprofit organization
- Offer grant writing or fundraising services for a nonprofit organization
- Provide community outreach or engagement services for a business or nonprofit organization
- Offer public speaking or presentation training services
- Provide executive coaching or leadership development services
- Offer team-building or corporate retreat planning services
- Provide conflict resolution or mediation services
- Offer executive search or recruitment services
- Provide employee training or development services
- Offer HR consulting or employment law services
- Provide compensation or benefits administration services
- Offer payroll or accounting services
- Provide bookkeeping or financial reporting services
- Offer tax preparation or planning services
- Provide business valuation or appraisal services
- Offer mergers and acquisitions advisory services
- Provide strategic planning or business consulting services
- Offer market research or competitive analysis services
- Provide data analysis or business intelligence services
- Offer project management or implementation services
- Provide quality control or assurance services
- Offer supply chain management or logistics services
- Provide inventory management or procurement services
- Offer customer relationship management or sales support services
2023.03.20 16:11 AutoModerator [Get] Simpler Trading – Bulletproof Butterflies 2.0 Elite by Bruce Marshall Download course on Genkicourses.com
![[Get] Simpler Trading – Bulletproof Butterflies 2.0 Elite by Bruce Marshall Download course on Genkicourses.com](https://b.thumbs.redditmedia.com/tGYBOFFgsgbXLIF11lsoRUYQX7UUak8AlzVgLgNvf0Y.jpg "[Get] Simpler Trading – Bulletproof Butterflies 2.0 Elite by Bruce Marshall Download course on Genkicourses.com") | Get the course here: https://www.genkicourses.com/product/simpler-trading-bulletproof-butterflies-2-0-elite/ submitted by AutoModerator to G3nki_Courses_ [link] [comments] [Get] Simpler Trading – Bulletproof Butterflies 2.0 Elite by Bruce Marshall Download course on Genkicourses.com https://preview.redd.it/3qw652ifeqoa1.jpg?width=1280&format=pjpg&auto=webp&s=236c11fdf4ac5968bb61e3b75145f0e84bbd229f BULLETPROOF BUTTERFLIES (ELITE PACKAGE) – SIMPLER TRADING BY BRUCE MARSHALLBeat Volatile Markets… With ‘Bulletproof Butterflies’ Use this Weekly Options Strategy to Boost Short-Term GainsWHO IS BRUCE MARSHALL?Director of Options and Income TradingBruce is a devoted mentor here at Simpler. After spending many years on Wall Street managing institutional and retail accounts, we’re lucky to have him trading in several memberships of ours. In addition to the Options Chatroom, he has his own service called Bruce’s Income Accumulation System (BIAS), where he focuses heavily on some of his favorite strategies. If you’re looking to improve you risk/reward ratio, or you’re not able to devote large amounts of time sitting watching the charts, Bruce may be just the trader you’re looking for. As his trades develop over a longer span of time — sometimes even months at a time. First and foremost though, if you want to know more about the Greeks, there’s no one better than Bruce. DO YOU STRUGGLE WITH GENERATING CONSISTENT INCOME THROUGH CRAZY MARKET UPS AND DOWNS?With all that’s happening in the world, the market once again kicked into “crazy” mode. You’ll have to adjust your trading strategy, or watch your account balance plummet with no hope of recovery.That’s why Bruce Marshall developed a new twist to a reliable short-term setup — so you can turn these swings into weekly income! The goal is to set the trade, let it work, and then come back a short time later and take the gains. With the “Bulletproof Butterflies” setup we were in and out of the trade in four hours with $700 profit. This is right in line with a target of making $250 – $500 in consistent weekly income. Just imagine averaging one trade like this each week. That kind of steady cash flow can really add up. THERE’S SERIOUS MONEY IN THE MARKET… WITH THE RIGHT TOOLSWhat’s great about “Bulletproof Butterflies” is that you can profit even if the market doesn’t move as you expect. Plus, you can defend these positions easily if need be…Bruce poured his 30+ years of experience as a full-time trader into this strategy. He made a name for himself managing 100-plus million-dollar funds on Wall Street. “Bulletproof Butterflies” is his answer to repeated questions from new and seasoned traders wanting to develop consistent income. When you trade an uncertain market, you know a nice upward trend won’t last — maybe not even a few hours. So the question becomes how to make consistent money? Bruce sticks to what has worked for years… a time-tested butterfly strategy for any trend in the market. “Bulletproof Butterflies” are great because they’re meant to be flexible. So you don’t have to be “dead on” correct to come out on top! You can trade them small or stack them, and they’re designed for short-term cash flow. There’s plenty of money to be made in this market, you just need the right tools. In Bruce’s income class, you will discover: How to “dial” up or down your risk over the life of the trade. The complete details of this low-maintenance setup. Learn a simple weekly strategy that works over and over in bullish or bearish conditions. How to instantly tell a good setup from a bad one and properly calculate your risk vs. reward. Learn the pros and cons of trading weeklies. What to do when your trade gets into trouble. And a whole lot more… |
2023.03.20 16:00 _call-me-al_ [Mon, Mar 20 2023] TL;DR — This is what you missed in the last 24 hours on Reddit
If you want to receive this as a daily email in your inbox, you can now join at this link
worldnews
Polish Ambassador to France: Poland will be forced to enter war if Ukraine fails to defend itselfComments Link
Ukrainian officials express outrage over Putin's surprise visit to city of Mariupol, saying visiting under the cover of night "befits a thief"
Comments Link
French President Emanuel Macron faces a critical test on Monday when the National Assembly is due to examine no-confidence motions filed after his government bypassed parliament on Thursday to push through a deeply unpopular pension reform, sparking days of unrest
Comments Link
news
Alex Jones reportedly concealing funds to avoid $1.5bn payout to Sandy Hook familiesComments Link
US Christian group accused of covering up sexual abuse of minors US news
Comments Link
Texas abortion law means woman has to continue pregnancy despite fatal anomaly
Comments Link
science
Study: 59% of Neighborhoods in Canada Within a 5-Minute Drive of a Cannabis StoreComments Link
Individuals who live in areas that historically favored men over women display more pro-male bias today than those who live in places where gender relations were more egalitarian centuries ago—evidence that gender attitudes are “transmitted” or handed down from generation to generation.
Comments Link
Bird flu is associated with more than 330 seal deaths in New England — linking H5N1 strain to a large scale mortality event in wild mammals
Comments Link
space
Close up of Pluto from the New Horizons space probeComments Link
My homebuilt observatory-grade telescope that fits in the back of an SUV
Comments Link
Sights and sounds from the surface of Mars.
Comments Link
Futurology
The Matrix is here! Using ChatGPT 4 to play as an ensign in Star TrekComments Link
Anticancer Activity of Bee Venom Components against Breast Cancer
Comments Link
Scientists grow antlers on mice, hope to regrow human limbs
Comments Link
AskReddit
Americans, what do Eurpoeans have everyday that you see as a luxury?Comments Link
What made you suddenly lose interest in someone you were pursuing?
Comments Link
What’s the secret to good sex?
Comments Link
todayilearned
TIL that the reason we see fewer fireflies nowadays is because there are genuinely fewer of them. 1 in 3 North American firefly species are at risk of extinction, with some species already being officially listed as 'Critically Endangered'!Comments Link
TIL That, shortly after the Berlin Wall fell, Eugene Stoner, inventor of the AR-15, and Mikhail Kalashnikov, inventor of the AK-47, met near Washington DC and developed a friendship that lasted until Stoner's death seven years later.
Comments Link
TIL a man suffering from fatal familial insomnia, a condition whereby you become biologically incapable of sleep, attempted vitamin therapy, sensory deprivation, narcoleptics, and anesthesia to sleep, which prolonged his life by 12 months.
Comments Link
dataisbeautiful
Bar chart of the summarized hight of all 2x2 LEGO DUPLO bricks my son owns, ordered by color. It's his first bar graph, so please be gentle. [OC]Comments Link
[Oc] El Salvador had the highest homicide rate in Latin America. Since its peak in 2015, the rate has decreased an incredible 92%.
Comments Link
[OC] Heapsort algorithm sorting a reversed list
Comments Link
Cooking
Burger seasoning other than salt and pepper?Comments Link
Uses for miso paste?
Comments Link
Keeping a Clean Kitchen
Comments Link
food
[homemade] TiramisuComments Link
[Homemade] Fruit Platter pirate ship
Comments Link
[homemade] NY-style pizzas
Comments Link
movies
'Catch Me If You Can' conman Frank Abagnale lied about his lies.Comments Link
The IMAX poster for Shin Kamen Rider, released in Japan on March 18th, 2023
Comments Link
Describe a movie's plot via acronym of the movie's title
Comments Link
Art
Duck, Me, Watercolour, 2023Comments Link
Polygonal sculpture "Lions", Me, metal, 2023
Comments Link
Underwater world, me, wood/resin, 2023
Comments Link
television
I'm Bob Odenkirk and I'm feeling pretty lucky. AMA!Comments Link
‘Better Call Saul’ Season 6 is Coming to Netflix (US) on April 18
Comments Link
Adam Sandler To Receive Mark Twain Prize For Lifetime In Comedy
Comments Link
pics
My dad made me take pics 4 his dating websites, here’s him yelling at me while striking a sexy pose.Comments Link
The size difference between my 1970 Honda and a regular pickup truck.
Comments Link
I was riding my bike under a rainbow through a shower
Comments Link
gifs
BF-FurEVER!Comments Link
Little Piggy has the zoomies
Comments Link
The Promise We Made at Sunset/夕阳下许下的承诺
Comments Link
educationalgifs
Galactic year (or a cosmic year) is the time that the Sun takes to orbit once around the center of the Milky Way Galaxy. We move 230 km every second (143 mi/s) in orbit around the center (less than 0.1% of light speed).Comments Link
How a decorative glass plate is made -
Comments Link
mildlyinteresting
My sink sprayer has a tough spot remover. It shoots a high pressure stream down the middle that is surprisingly powerful, but a cone of water around it that blocks all the splashesComments Link
Home Depot left the sprinklers on overnight in freezing weather
Comments Link
This weekend I stumbled upon the gravestone for Michael Bond, the author of Paddington Bear.
Comments Link
interestingasfuck
On April 28, 1988, the roof of an Aloha Airlines jet ripped off at 24,000 feet, but the plane still managed to land safely.Comments Link
Excited group digging up a crystal
Comments Link
Colombian Angel Alvarado solves three Rubik’s Cubes while juggling them
Comments Link
funny
Edge-Man [OC]Comments Link
My wife's foolproof method of chopping onions with zero tears
Comments Link
John Wick housecleaning service
Comments Link
aww
This boy’s reaction to seeing his newborn sister for the first timeComments Link
Baby penguin flippy flaps.
Comments Link
The little cat pictured is one of my favorites
Comments Link
2023.03.20 15:36 Rias0 Welcher PC ist besser
Ich versuche mich jetzt zu entscheiden, einen gebrauchten PC zu kaufen, und ich gucke mir gerade zwei PCs an.
Der erste für 1850€:
Betriebssystem: Windows 11 Pro Gehäuse: Lian Li-PC-011 Dynamic Weiß
CPU: AMD Ryzen 9 5950X
Mainboard: ASUS ROG Strix X570-E Grafikkarte: RTX 3080 Ti Gigayte Gaming Arbeitsspeicher: 64GB DDR4 Corsair RGB M.2 SSD: 1TB Samsung 980 PRO
HDD: 2TB Western Digital WD Red Netzteil: 1000W Corsair RMX Series Wasserkühlung: Corsair iCUE H150i Elite Gehäuselüfter: 3x Corsair RGB
Und der zweite für 1700€:
Corsair ICUE 4000X
RGB schwarz mit Glasfenster
Intel 17-12700KF mit 12x 3.60GHz/ 5.00GHz Turbotakt,
25 MB Cache
Corsair H1501 Elite Capellix schwarz
MSI PRO Z690-A
DDR4
16 GB (2 x 8 GB) DDR4-Corsair
3600 MHz
Rache RGB
PROSL
1 TB MSI Space PCle4.0 x4 NVMe
(L: 7000 MB/s; S: 5500 MB/s)
10GB MSI RTX3080 GAMING Z TRIO
(LHR)
850W be quiet! Gerade Macht 11
Platin
kein Laufwerk
Garantie und
Service
2 Jahre Garantie
Software
Windows 10 Pro 64bit (Installiert inkl Key)
Bullguard Internet Security 1-Jahr- Lizenz (3 Geräte)
Welcher ist besser? (unabhängig vom Preis).
submitted by Rias0 to PCBaumeister [link] [comments]
Der erste für 1850€:
Betriebssystem: Windows 11 Pro Gehäuse: Lian Li-PC-011 Dynamic Weiß
CPU: AMD Ryzen 9 5950X
Mainboard: ASUS ROG Strix X570-E Grafikkarte: RTX 3080 Ti Gigayte Gaming Arbeitsspeicher: 64GB DDR4 Corsair RGB M.2 SSD: 1TB Samsung 980 PRO
HDD: 2TB Western Digital WD Red Netzteil: 1000W Corsair RMX Series Wasserkühlung: Corsair iCUE H150i Elite Gehäuselüfter: 3x Corsair RGB
Und der zweite für 1700€:
Corsair ICUE 4000X
RGB schwarz mit Glasfenster
Intel 17-12700KF mit 12x 3.60GHz/ 5.00GHz Turbotakt,
25 MB Cache
Corsair H1501 Elite Capellix schwarz
MSI PRO Z690-A
DDR4
16 GB (2 x 8 GB) DDR4-Corsair
3600 MHz
Rache RGB
PROSL
1 TB MSI Space PCle4.0 x4 NVMe
(L: 7000 MB/s; S: 5500 MB/s)
10GB MSI RTX3080 GAMING Z TRIO
(LHR)
850W be quiet! Gerade Macht 11
Platin
kein Laufwerk
Garantie und
Service
2 Jahre Garantie
Software
Windows 10 Pro 64bit (Installiert inkl Key)
Bullguard Internet Security 1-Jahr- Lizenz (3 Geräte)
Welcher ist besser? (unabhängig vom Preis).
2023.03.20 15:31 SituationLive4406 NASDAQ: MYNZ Multiple Catalysts Ahead
 | Hello everyone, submitted by SituationLive4406 to Biotechplays [link] [comments] Today I have a diagnostics biotech company with near-term catalysts, small float, potential chart breakout, great news just released and recent analyst coverage indicating over 120% upside (See Analyst Reports Below). This one has demonstrated the ability to run up fast in recent months! Note\* Mainz Biomed's ColoAlert test is currently approved and commercially available in Europe and select International markets. Sales, commercial partnerships and marketing activities are starting to ramp up NOW! This leaves an open door for multiple near-term catalysts. Mainz Biomed B.V. (NASDAQ: MYNZ) a molecular genetics diagnostic company specializing in the early detection of cancer. The company operates a clinical diagnostic laboratory and generates the majority of its revenue from in-licensed CE-IVD marked stool-based colorectal cancer (CRC) detection test ColoAlert. While working to expand ColoAlert sales in European markets, Mainz is developing potential improvements for a second generation product. While the first generation of ColoAlert combines the fecal immunochemical test (FIT) with multiple DNA mutation markers to detect early stage CRC, the company is investigating the addition of novel mRNA biomarkers that may be able to detect pre-cancerous polyps with best-in-class potential. Clinical data from patients treated at the Hamamatsu University School of Medicine (Japan) and the Centre Hospitalier Universitaire de Sherbrooke (CHUS; Canada) indicate that the mRNA biomarkers being tested are able to achieve high sensitivity and specificity (published results here) and Mainz is expected to release its own feasibility study results in 1H23. Following Our Last Report, Mainz Biomed in a Very Smart Move Acquired the Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program Excerpt from this article: “This is an important value generation milestone for us as we continue executing our commercial strategy and product development plan to ultimately bring to market the gold-standard CRC self-administered diagnostic test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Securing complete IP ownership is integral to our growth strategy as it streamlines administration, reduces per-test expenses, and provides us the opportunity to ramp-up corporate development activities,” added Baechler. FULL ARTICLE Recent News, Another Catalyst Announced Last Week Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany Labor Staber to actively market and sell ColoAlert to its physician and patient network. BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber & Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany. FULL ARTICLE Mainz Biomed Enters Commercial Partnerships for ColoAlert with two Independent Laboratories News Issued Feb. 15, 2023 - Mainz Biomed (NASDAQ: MYNZ) on Wednesday has formed commercial partnerships for ColoAlert with Marylebone Laboratory and Instituto de Microecologia, two leading independent laboratories covering England and Spain. Mainz (MYNZ) markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe and being commercialized in select international markets via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. In the forthcoming weeks, Mainz Biomed will work with both partners to complete the necessary technical and co-marketing activities to ensure a successful commercial launch in these markets. Full Press Release Mainz Draws Bullish Views at Cantor Fitzgerald on Potential in Colorectal Cancer Screening October 25th, 2022 - Cancer test maker Mainz Biomed B.V. (NASDAQ: MYNZ) Cantor Fitzgerald initiated its coverage with an Overweight recommendation noting the company’s prospects in colorectal cancer screening. Mainz (MYNZ) markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe, and its “European sales provide near-term revenue potential while the company prepares to enter the U.S. market,” the analyst Ross Osborn argues. The analyst issues positive views on the E.U. and U.S. CRC screening market, estimated at $13B, and notes that the company’s partnership model is likely to improve the adoption of ColoAlert compared to a direct-marketing approach. Commenting on MYNZ’s valuation disparity with Exact Sciences Corporation (EXAS), its U.S.-based rival in colorectal screening, Osborn argues that the company can close the valuation gap as its sales “volumes accelerate and ColoAlert receives FDA approval.” The price target at $15 implies over 120% upside to yesterday's closing price but stands lower than the current average price target for MYNZ on Wall Street. Full Cantor Fitzgerald Report Jones Research Initiated February 9th, 2023 - Staking Its Claim in the Booming CRC Screening Market Initiating with Buy Rating and $11 PT Jones Research Report Highlights "The future: one sample – multiple screenings. In addition to efforts to improve early detection by incorporating mRNA biomarkers into ColoAlert, Mainz is developing PancAlert. PancAlert is a stool-based early detection screening test for pancreatic cancer. While the company is still evaluating the sensitivity of the product and it remains in the early research stage, we are intrigued by the possibilities of screening for multiple cancers using the same stool-sample (i.e., making use of both ColoAlert and PancAlert). Not only could this offer considerable synergies for Mainz, but it could also improve patient outcomes with no increased inconvenience. Theoretically, the company could expand beyond CRC and pancreatic cancer from there and provide early detection of multiple cancers that are amenable to stool-based screening. While we wait for clinical validation of PancAlert, however, we are not including future revenues in our model and leave the product as a source of potential upside for investors." "Key Catalyst: mRNA feasibility study readout (1H23); 2) begin enrollment in pivotal ReconAAsense trial (mid-2023)." "Valuation: Our $11 price target is based on risk-adjusted discounted cash flow (DCF) valuation with cash flows forecasted through 2034, along with a 12.5% discount rate and a 0% terminal growth rate. We assume a probability of success of 90% for ColoAlert in the U.S." Full Jones Research Report MYNZ Statistics as of the Most Recent Quarter (mrq) Cash on Hand $26M Market Cap $95M Shares Outstanding 14.49M Shares in Float 11M Held by Insiders 23.79% source: Yahoo Finance The market for MYNZ's ColoAlert is massive and it will not take a very big percentage of market share to catapult this little biotech in to the stratosphere. https://preview.redd.it/c6xo37zzmwoa1.png?width=1516&format=png&auto=webp&s=1a5d1f160a98f8f646c8bbcfefd87f8649d89c74 Source: MYNZ Corporate Presentation How Important is Early Detection? IT SAVES LIVES! https://preview.redd.it/aeb33vs0nwoa1.png?width=1179&format=png&auto=webp&s=f5d9d809ceb6795df17cd2da69e862194740d2d2 Source: MYNZ Corporate Presentation Should Mainz Biomed goal of combining the Colorectal and Pancreatic tests in to one, we could be looking back on this report as one of our biggest winners ever. Disclaimer |
2023.03.20 15:30 SituationLive4406 MYNZ Multiple Catalysts Ahead
 | Hello everyone, submitted by SituationLive4406 to biotech_stocks [link] [comments] Today I have a diagnostics biotech company with near-term catalysts, small float, potential chart breakout, great news just released and recent analyst coverage indicating over 120% upside (See Analyst Reports Below). This one has demonstrated the ability to run up fast in recent months! Note\* Mainz Biomed's ColoAlert test is currently approved and commercially available in Europe and select International markets. Sales, commercial partnerships and marketing activities are starting to ramp up NOW! This leaves an open door for multiple near-term catalysts. Mainz Biomed B.V. (NASDAQ: MYNZ) a molecular genetics diagnostic company specializing in the early detection of cancer. The company operates a clinical diagnostic laboratory and generates the majority of its revenue from in-licensed CE-IVD marked stool-based colorectal cancer (CRC) detection test ColoAlert. While working to expand ColoAlert sales in European markets, Mainz is developing potential improvements for a second generation product. While the first generation of ColoAlert combines the fecal immunochemical test (FIT) with multiple DNA mutation markers to detect early stage CRC, the company is investigating the addition of novel mRNA biomarkers that may be able to detect pre-cancerous polyps with best-in-class potential. Clinical data from patients treated at the Hamamatsu University School of Medicine (Japan) and the Centre Hospitalier Universitaire de Sherbrooke (CHUS; Canada) indicate that the mRNA biomarkers being tested are able to achieve high sensitivity and specificity (published results here) and Mainz is expected to release its own feasibility study results in 1H23. Following Our Last Report, Mainz Biomed in a Very Smart Move Acquired the Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program Excerpt from this article: “This is an important value generation milestone for us as we continue executing our commercial strategy and product development plan to ultimately bring to market the gold-standard CRC self-administered diagnostic test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Securing complete IP ownership is integral to our growth strategy as it streamlines administration, reduces per-test expenses, and provides us the opportunity to ramp-up corporate development activities,” added Baechler. FULL ARTICLE Recent News, Another Catalyst Announced Last Week Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany Labor Staber to actively market and sell ColoAlert to its physician and patient network. BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber & Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany. FULL ARTICLE Mainz Biomed Enters Commercial Partnerships for ColoAlert with two Independent Laboratories News Issued Feb. 15, 2023 - Mainz Biomed (NASDAQ: MYNZ) on Wednesday has formed commercial partnerships for ColoAlert with Marylebone Laboratory and Instituto de Microecologia, two leading independent laboratories covering England and Spain. Mainz (MYNZ) markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe and being commercialized in select international markets via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. In the forthcoming weeks, Mainz Biomed will work with both partners to complete the necessary technical and co-marketing activities to ensure a successful commercial launch in these markets. Full Press Release Mainz Draws Bullish Views at Cantor Fitzgerald on Potential in Colorectal Cancer Screening October 25th, 2022 - Cancer test maker Mainz Biomed B.V. (NASDAQ: MYNZ) Cantor Fitzgerald initiated its coverage with an Overweight recommendation noting the company’s prospects in colorectal cancer screening. Mainz (MYNZ) markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe, and its “European sales provide near-term revenue potential while the company prepares to enter the U.S. market,” the analyst Ross Osborn argues. The analyst issues positive views on the E.U. and U.S. CRC screening market, estimated at $13B, and notes that the company’s partnership model is likely to improve the adoption of ColoAlert compared to a direct-marketing approach. Commenting on MYNZ’s valuation disparity with Exact Sciences Corporation (EXAS), its U.S.-based rival in colorectal screening, Osborn argues that the company can close the valuation gap as its sales “volumes accelerate and ColoAlert receives FDA approval.” The price target at $15 implies over 120% upside to yesterday's closing price but stands lower than the current average price target for MYNZ on Wall Street. Full Cantor Fitzgerald Report Jones Research Initiated February 9th, 2023 - Staking Its Claim in the Booming CRC Screening Market Initiating with Buy Rating and $11 PT Jones Research Report Highlights "The future: one sample – multiple screenings. In addition to efforts to improve early detection by incorporating mRNA biomarkers into ColoAlert, Mainz is developing PancAlert. PancAlert is a stool-based early detection screening test for pancreatic cancer. While the company is still evaluating the sensitivity of the product and it remains in the early research stage, we are intrigued by the possibilities of screening for multiple cancers using the same stool-sample (i.e., making use of both ColoAlert and PancAlert). Not only could this offer considerable synergies for Mainz, but it could also improve patient outcomes with no increased inconvenience. Theoretically, the company could expand beyond CRC and pancreatic cancer from there and provide early detection of multiple cancers that are amenable to stool-based screening. While we wait for clinical validation of PancAlert, however, we are not including future revenues in our model and leave the product as a source of potential upside for investors." "Key Catalyst: mRNA feasibility study readout (1H23); 2) begin enrollment in pivotal ReconAAsense trial (mid-2023)." "Valuation: Our $11 price target is based on risk-adjusted discounted cash flow (DCF) valuation with cash flows forecasted through 2034, along with a 12.5% discount rate and a 0% terminal growth rate. We assume a probability of success of 90% for ColoAlert in the U.S." Full Jones Research Report MYNZ Statistics as of the Most Recent Quarter (mrq) Cash on Hand $26M Market Cap $95M Shares Outstanding 14.49M Shares in Float 11M Held by Insiders 23.79% source: Yahoo Finance The market for MYNZ's ColoAlert is massive and it will not take a very big percentage of market share to catapult this little biotech in to the stratosphere. https://preview.redd.it/sshrukcqmwoa1.png?width=1516&format=png&auto=webp&s=2fb9cac8a7468eabf81c9c4a155ddf6237a6cbc3 Source: MYNZ Corporate Presentation How Important is Early Detection? IT SAVES LIVES! https://preview.redd.it/5w4ikx2rmwoa1.png?width=1179&format=png&auto=webp&s=b09db6c9cbbcf22961aefbb8738891e324b760d7 Source: MYNZ Corporate Presentation Should Mainz Biomed goal of combining the Colorectal and Pancreatic tests in to one, we could be looking back on this report as one of our biggest winners ever. Disclaimer |
2023.03.20 15:25 Acx99 Journalist Request: How has the cost of living crisis impacted your access to therapy? [Scotland Based]
Hi MentalHealthUK
I’m a BBC Scotland journalism apprentice looking to hear how the rising cost of living is impacting people who use mental health services.
Have you had to make financial sacrifices to continue using your services? Or have you had to cut back on sessions or cut out therapy/counselling all together?
At this stage it’s more for research purposes to hear what people are experiencing.
Any information given to me will remain anonymous and won’t be used in any articles until and unless we both agree to have a more formal interview either in person or via a call to establish what you would be comfortable sharing to the wider media.
If you have any further questions and or concerns please let me know!
I can be reached here on Reddit or via my work email: [email protected]
Hope to hear from you
submitted by Acx99 to MentalHealthUK [link] [comments]
I’m a BBC Scotland journalism apprentice looking to hear how the rising cost of living is impacting people who use mental health services.
Have you had to make financial sacrifices to continue using your services? Or have you had to cut back on sessions or cut out therapy/counselling all together?
At this stage it’s more for research purposes to hear what people are experiencing.
Any information given to me will remain anonymous and won’t be used in any articles until and unless we both agree to have a more formal interview either in person or via a call to establish what you would be comfortable sharing to the wider media.
If you have any further questions and or concerns please let me know!
I can be reached here on Reddit or via my work email: [email protected]
Hope to hear from you
2023.03.20 15:19 SituationLive4406 MYNZ Multiple Catalysts Ahead
Hello everyone and welcome to all our new members,
Today we have a diagnostics biotech company with near-term catalysts, small float, potential chart breakout, great news just released and recent analyst coverage indicating over 120% upside (See Analyst Reports Below).
This one has demonstrated the ability to run up fast in recent months!
Note\* Mainz Biomed's ColoAlert test is currently approved and commercially available in Europe and select International markets. Sales, commercial partnerships and marketing activities are starting to ramp up NOW! This leaves an open door for multiple near-term catalysts.
Mainz Biomed B.V. (NASDAQ: MYNZ) a molecular genetics diagnostic company specializing in the early detection of cancer.
The company operates a clinical diagnostic laboratory and generates the majority of its revenue from in-licensed CE-IVD marked stool-based colorectal cancer (CRC) detection test ColoAlert. While working to expand ColoAlert sales in European markets, Mainz is developing potential improvements for a second generation product. While the first generation of ColoAlert combines the fecal immunochemical test (FIT) with multiple DNA mutation markers to detect early stage CRC, the company is investigating the addition of novel mRNA biomarkers that may be able to detect pre-cancerous polyps with best-in-class potential. Clinical data from patients treated at the Hamamatsu University School of Medicine (Japan) and the Centre Hospitalier Universitaire de Sherbrooke (CHUS; Canada) indicate that the mRNA biomarkers being tested are able to achieve high sensitivity and specificity (published results here) and Mainz is expected to release its own feasibility study results in 1H23.
Following Our Last Report, Mainz Biomed in a Very Smart Move Acquired the Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
Excerpt from this article:
“This is an important value generation milestone for us as we continue executing our commercial strategy and product development plan to ultimately bring to market the gold-standard CRC self-administered diagnostic test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Securing complete IP ownership is integral to our growth strategy as it streamlines administration, reduces per-test expenses, and provides us the opportunity to ramp-up corporate development activities,” added Baechler. FULL ARTICLE
Recent News, Another Catalyst Announced Last Week
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
Labor Staber to actively market and sell ColoAlert to its physician and patient network.
BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber & Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany. FULL ARTICLE
Mainz Biomed Enters Commercial Partnerships for ColoAlert with two Independent Laboratories
News Issued Feb. 15, 2023 - Mainz Biomed (NASDAQ: MYNZ) on Wednesday has formed commercial partnerships for ColoAlert with Marylebone Laboratory and Instituto de Microecologia, two leading independent laboratories covering England and Spain.
Mainz (MYNZ) markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe and being commercialized in select international markets via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
In the forthcoming weeks, Mainz Biomed will work with both partners to complete the necessary technical and co-marketing activities to ensure a successful commercial launch in these markets. Full Press Release
Mainz Draws Bullish Views at Cantor Fitzgerald on Potential in Colorectal Cancer Screening
October 25th, 2022 - Cancer test maker Mainz Biomed B.V. (NASDAQ: MYNZ) Cantor Fitzgerald initiated its coverage with an Overweight recommendation noting the company’s prospects in colorectal cancer screening.
Mainz (MYNZ) markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe, and its “European sales provide near-term revenue potential while the company prepares to enter the U.S. market,” the analyst Ross Osborn argues.
The analyst issues positive views on the E.U. and U.S. CRC screening market, estimated at $13B, and notes that the company’s partnership model is likely to improve the adoption of ColoAlert compared to a direct-marketing approach.
Commenting on MYNZ’s valuation disparity with Exact Sciences Corporation (EXAS), its U.S.-based rival in colorectal screening, Osborn argues that the company can close the valuation gap as its sales “volumes accelerate and ColoAlert receives FDA approval.”
The price target at $15 implies over 120% upside to yesterday's closing price but stands lower than the current average price target for MYNZ on Wall Street. Full Cantor Fitzgerald Report
Jones Research Initiated February 9th, 2023 - Staking Its Claim in the Booming CRC Screening Market
Initiating with Buy Rating and $11 PT
Jones Research Report Highlights
"The future: one sample – multiple screenings. In addition to efforts to improve early detection by incorporating mRNA biomarkers into ColoAlert, Mainz is developing PancAlert. PancAlert is a stool-based early detection screening test for pancreatic cancer. While the company is still evaluating the sensitivity of the product and it remains in the early research stage, we are intrigued by the possibilities of screening for multiple cancers using the same stool-sample (i.e., making use of both ColoAlert and PancAlert). Not only could this offer considerable synergies for Mainz, but it could also improve patient outcomes with no increased inconvenience. Theoretically, the company could expand beyond CRC and pancreatic cancer from there and provide early detection of multiple cancers that are amenable to stool-based screening. While we wait for clinical validation of PancAlert, however, we are not including future revenues in our model and leave the product as a source of potential upside for investors."
"Key Catalyst: mRNA feasibility study readout (1H23); 2) begin enrollment in pivotal ReconAAsense trial (mid-2023)."
"Valuation: Our $11 price target is based on risk-adjusted discounted cash flow (DCF) valuation with cash flows forecasted through 2034, along with a 12.5% discount rate and a 0% terminal growth rate. We assume a probability of success of 90% for ColoAlert in the U.S." Full Jones Research Report
MYNZ Statistics as of the Most Recent Quarter (mrq)
Cash on Hand $26M Market Cap $95M Shares Outstanding 14.49M Shares in Float 11M Held by Insiders 23.79% source: Yahoo Finance
The market for MYNZ's ColoAlert is massive and it will not take a very big percentage of market share to catapult this little biotech in to the stratosphere.
📷 Source: MYNZ Corporate Presentation
How Important is Early Detection? IT SAVES LIVES!
📷 Source: MYNZ Corporate Presentation
Should Mainz Biomed goal of combining the Colorectal and Pancreatic tests in to one, we could be looking back on this report as one of our biggest winners ever.
Disclaimer
submitted by SituationLive4406 to BreakoutStocks [link] [comments]
Today we have a diagnostics biotech company with near-term catalysts, small float, potential chart breakout, great news just released and recent analyst coverage indicating over 120% upside (See Analyst Reports Below).
This one has demonstrated the ability to run up fast in recent months!
Note\* Mainz Biomed's ColoAlert test is currently approved and commercially available in Europe and select International markets. Sales, commercial partnerships and marketing activities are starting to ramp up NOW! This leaves an open door for multiple near-term catalysts.
Mainz Biomed B.V. (NASDAQ: MYNZ) a molecular genetics diagnostic company specializing in the early detection of cancer.
The company operates a clinical diagnostic laboratory and generates the majority of its revenue from in-licensed CE-IVD marked stool-based colorectal cancer (CRC) detection test ColoAlert. While working to expand ColoAlert sales in European markets, Mainz is developing potential improvements for a second generation product. While the first generation of ColoAlert combines the fecal immunochemical test (FIT) with multiple DNA mutation markers to detect early stage CRC, the company is investigating the addition of novel mRNA biomarkers that may be able to detect pre-cancerous polyps with best-in-class potential. Clinical data from patients treated at the Hamamatsu University School of Medicine (Japan) and the Centre Hospitalier Universitaire de Sherbrooke (CHUS; Canada) indicate that the mRNA biomarkers being tested are able to achieve high sensitivity and specificity (published results here) and Mainz is expected to release its own feasibility study results in 1H23.
Following Our Last Report, Mainz Biomed in a Very Smart Move Acquired the Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
Excerpt from this article:
“This is an important value generation milestone for us as we continue executing our commercial strategy and product development plan to ultimately bring to market the gold-standard CRC self-administered diagnostic test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Securing complete IP ownership is integral to our growth strategy as it streamlines administration, reduces per-test expenses, and provides us the opportunity to ramp-up corporate development activities,” added Baechler. FULL ARTICLE
Recent News, Another Catalyst Announced Last Week
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
Labor Staber to actively market and sell ColoAlert to its physician and patient network.
BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber & Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany. FULL ARTICLE
Mainz Biomed Enters Commercial Partnerships for ColoAlert with two Independent Laboratories
News Issued Feb. 15, 2023 - Mainz Biomed (NASDAQ: MYNZ) on Wednesday has formed commercial partnerships for ColoAlert with Marylebone Laboratory and Instituto de Microecologia, two leading independent laboratories covering England and Spain.
Mainz (MYNZ) markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe and being commercialized in select international markets via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
In the forthcoming weeks, Mainz Biomed will work with both partners to complete the necessary technical and co-marketing activities to ensure a successful commercial launch in these markets. Full Press Release
Mainz Draws Bullish Views at Cantor Fitzgerald on Potential in Colorectal Cancer Screening
October 25th, 2022 - Cancer test maker Mainz Biomed B.V. (NASDAQ: MYNZ) Cantor Fitzgerald initiated its coverage with an Overweight recommendation noting the company’s prospects in colorectal cancer screening.
Mainz (MYNZ) markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe, and its “European sales provide near-term revenue potential while the company prepares to enter the U.S. market,” the analyst Ross Osborn argues.
The analyst issues positive views on the E.U. and U.S. CRC screening market, estimated at $13B, and notes that the company’s partnership model is likely to improve the adoption of ColoAlert compared to a direct-marketing approach.
Commenting on MYNZ’s valuation disparity with Exact Sciences Corporation (EXAS), its U.S.-based rival in colorectal screening, Osborn argues that the company can close the valuation gap as its sales “volumes accelerate and ColoAlert receives FDA approval.”
The price target at $15 implies over 120% upside to yesterday's closing price but stands lower than the current average price target for MYNZ on Wall Street. Full Cantor Fitzgerald Report
Jones Research Initiated February 9th, 2023 - Staking Its Claim in the Booming CRC Screening Market
Initiating with Buy Rating and $11 PT
Jones Research Report Highlights
"The future: one sample – multiple screenings. In addition to efforts to improve early detection by incorporating mRNA biomarkers into ColoAlert, Mainz is developing PancAlert. PancAlert is a stool-based early detection screening test for pancreatic cancer. While the company is still evaluating the sensitivity of the product and it remains in the early research stage, we are intrigued by the possibilities of screening for multiple cancers using the same stool-sample (i.e., making use of both ColoAlert and PancAlert). Not only could this offer considerable synergies for Mainz, but it could also improve patient outcomes with no increased inconvenience. Theoretically, the company could expand beyond CRC and pancreatic cancer from there and provide early detection of multiple cancers that are amenable to stool-based screening. While we wait for clinical validation of PancAlert, however, we are not including future revenues in our model and leave the product as a source of potential upside for investors."
"Key Catalyst: mRNA feasibility study readout (1H23); 2) begin enrollment in pivotal ReconAAsense trial (mid-2023)."
"Valuation: Our $11 price target is based on risk-adjusted discounted cash flow (DCF) valuation with cash flows forecasted through 2034, along with a 12.5% discount rate and a 0% terminal growth rate. We assume a probability of success of 90% for ColoAlert in the U.S." Full Jones Research Report
MYNZ Statistics as of the Most Recent Quarter (mrq)
Cash on Hand $26M Market Cap $95M Shares Outstanding 14.49M Shares in Float 11M Held by Insiders 23.79% source: Yahoo Finance
The market for MYNZ's ColoAlert is massive and it will not take a very big percentage of market share to catapult this little biotech in to the stratosphere.
📷 Source: MYNZ Corporate Presentation
How Important is Early Detection? IT SAVES LIVES!
📷 Source: MYNZ Corporate Presentation
Should Mainz Biomed goal of combining the Colorectal and Pancreatic tests in to one, we could be looking back on this report as one of our biggest winners ever.
Disclaimer
2023.03.20 15:18 SituationLive4406 MYNZ Multiple Catalysts Ahead
Hello everyone and welcome to all our new members,
Today we have a diagnostics biotech company with near-term catalysts, small float, potential chart breakout, great news just released and recent analyst coverage indicating over 120% upside (See Analyst Reports Below).
This one has demonstrated the ability to run up fast in recent months!
Note\* Mainz Biomed's ColoAlert test is currently approved and commercially available in Europe and select International markets. Sales, commercial partnerships and marketing activities are starting to ramp up NOW! This leaves an open door for multiple near-term catalysts.
Mainz Biomed B.V. (NASDAQ: MYNZ) a molecular genetics diagnostic company specializing in the early detection of cancer.
The company operates a clinical diagnostic laboratory and generates the majority of its revenue from in-licensed CE-IVD marked stool-based colorectal cancer (CRC) detection test ColoAlert. While working to expand ColoAlert sales in European markets, Mainz is developing potential improvements for a second generation product. While the first generation of ColoAlert combines the fecal immunochemical test (FIT) with multiple DNA mutation markers to detect early stage CRC, the company is investigating the addition of novel mRNA biomarkers that may be able to detect pre-cancerous polyps with best-in-class potential. Clinical data from patients treated at the Hamamatsu University School of Medicine (Japan) and the Centre Hospitalier Universitaire de Sherbrooke (CHUS; Canada) indicate that the mRNA biomarkers being tested are able to achieve high sensitivity and specificity (published results here) and Mainz is expected to release its own feasibility study results in 1H23.
Following Our Last Report, Mainz Biomed in a Very Smart Move Acquired the Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
Excerpt from this article:
“This is an important value generation milestone for us as we continue executing our commercial strategy and product development plan to ultimately bring to market the gold-standard CRC self-administered diagnostic test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Securing complete IP ownership is integral to our growth strategy as it streamlines administration, reduces per-test expenses, and provides us the opportunity to ramp-up corporate development activities,” added Baechler. FULL ARTICLE
Recent News, Another Catalyst Announced Last Week
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
Labor Staber to actively market and sell ColoAlert to its physician and patient network.
BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber & Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany. FULL ARTICLE
Mainz Biomed Enters Commercial Partnerships for ColoAlert with two Independent Laboratories
News Issued Feb. 15, 2023 - Mainz Biomed (NASDAQ: MYNZ) on Wednesday has formed commercial partnerships for ColoAlert with Marylebone Laboratory and Instituto de Microecologia, two leading independent laboratories covering England and Spain.
Mainz (MYNZ) markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe and being commercialized in select international markets via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
In the forthcoming weeks, Mainz Biomed will work with both partners to complete the necessary technical and co-marketing activities to ensure a successful commercial launch in these markets. Full Press Release
Mainz Draws Bullish Views at Cantor Fitzgerald on Potential in Colorectal Cancer Screening
October 25th, 2022 - Cancer test maker Mainz Biomed B.V. (NASDAQ: MYNZ) Cantor Fitzgerald initiated its coverage with an Overweight recommendation noting the company’s prospects in colorectal cancer screening.
Mainz (MYNZ) markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe, and its “European sales provide near-term revenue potential while the company prepares to enter the U.S. market,” the analyst Ross Osborn argues.
The analyst issues positive views on the E.U. and U.S. CRC screening market, estimated at $13B, and notes that the company’s partnership model is likely to improve the adoption of ColoAlert compared to a direct-marketing approach.
Commenting on MYNZ’s valuation disparity with Exact Sciences Corporation (EXAS), its U.S.-based rival in colorectal screening, Osborn argues that the company can close the valuation gap as its sales “volumes accelerate and ColoAlert receives FDA approval.”
The price target at $15 implies over 120% upside to yesterday's closing price but stands lower than the current average price target for MYNZ on Wall Street. Full Cantor Fitzgerald Report
Jones Research Initiated February 9th, 2023 - Staking Its Claim in the Booming CRC Screening Market
Initiating with Buy Rating and $11 PT
Jones Research Report Highlights
"The future: one sample – multiple screenings. In addition to efforts to improve early detection by incorporating mRNA biomarkers into ColoAlert, Mainz is developing PancAlert. PancAlert is a stool-based early detection screening test for pancreatic cancer. While the company is still evaluating the sensitivity of the product and it remains in the early research stage, we are intrigued by the possibilities of screening for multiple cancers using the same stool-sample (i.e., making use of both ColoAlert and PancAlert). Not only could this offer considerable synergies for Mainz, but it could also improve patient outcomes with no increased inconvenience. Theoretically, the company could expand beyond CRC and pancreatic cancer from there and provide early detection of multiple cancers that are amenable to stool-based screening. While we wait for clinical validation of PancAlert, however, we are not including future revenues in our model and leave the product as a source of potential upside for investors."
"Key Catalyst: mRNA feasibility study readout (1H23); 2) begin enrollment in pivotal ReconAAsense trial (mid-2023)."
"Valuation: Our $11 price target is based on risk-adjusted discounted cash flow (DCF) valuation with cash flows forecasted through 2034, along with a 12.5% discount rate and a 0% terminal growth rate. We assume a probability of success of 90% for ColoAlert in the U.S." Full Jones Research Report
MYNZ Statistics as of the Most Recent Quarter (mrq)
Cash on Hand $26M Market Cap $95M Shares Outstanding 14.49M Shares in Float 11M Held by Insiders 23.79% source: Yahoo Finance
The market for MYNZ's ColoAlert is massive and it will not take a very big percentage of market share to catapult this little biotech in to the stratosphere.
📷 Source: MYNZ Corporate Presentation
How Important is Early Detection? IT SAVES LIVES!
📷 Source: MYNZ Corporate Presentation
Should Mainz Biomed goal of combining the Colorectal and Pancreatic tests in to one, we could be looking back on this report as one of our biggest winners ever.
Disclaimer
submitted by SituationLive4406 to SmallCapGrowth [link] [comments]
Today we have a diagnostics biotech company with near-term catalysts, small float, potential chart breakout, great news just released and recent analyst coverage indicating over 120% upside (See Analyst Reports Below).
This one has demonstrated the ability to run up fast in recent months!
Note\* Mainz Biomed's ColoAlert test is currently approved and commercially available in Europe and select International markets. Sales, commercial partnerships and marketing activities are starting to ramp up NOW! This leaves an open door for multiple near-term catalysts.
Mainz Biomed B.V. (NASDAQ: MYNZ) a molecular genetics diagnostic company specializing in the early detection of cancer.
The company operates a clinical diagnostic laboratory and generates the majority of its revenue from in-licensed CE-IVD marked stool-based colorectal cancer (CRC) detection test ColoAlert. While working to expand ColoAlert sales in European markets, Mainz is developing potential improvements for a second generation product. While the first generation of ColoAlert combines the fecal immunochemical test (FIT) with multiple DNA mutation markers to detect early stage CRC, the company is investigating the addition of novel mRNA biomarkers that may be able to detect pre-cancerous polyps with best-in-class potential. Clinical data from patients treated at the Hamamatsu University School of Medicine (Japan) and the Centre Hospitalier Universitaire de Sherbrooke (CHUS; Canada) indicate that the mRNA biomarkers being tested are able to achieve high sensitivity and specificity (published results here) and Mainz is expected to release its own feasibility study results in 1H23.
Following Our Last Report, Mainz Biomed in a Very Smart Move Acquired the Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
Excerpt from this article:
“This is an important value generation milestone for us as we continue executing our commercial strategy and product development plan to ultimately bring to market the gold-standard CRC self-administered diagnostic test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Securing complete IP ownership is integral to our growth strategy as it streamlines administration, reduces per-test expenses, and provides us the opportunity to ramp-up corporate development activities,” added Baechler. FULL ARTICLE
Recent News, Another Catalyst Announced Last Week
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
Labor Staber to actively market and sell ColoAlert to its physician and patient network.
BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber & Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany. FULL ARTICLE
Mainz Biomed Enters Commercial Partnerships for ColoAlert with two Independent Laboratories
News Issued Feb. 15, 2023 - Mainz Biomed (NASDAQ: MYNZ) on Wednesday has formed commercial partnerships for ColoAlert with Marylebone Laboratory and Instituto de Microecologia, two leading independent laboratories covering England and Spain.
Mainz (MYNZ) markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe and being commercialized in select international markets via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
In the forthcoming weeks, Mainz Biomed will work with both partners to complete the necessary technical and co-marketing activities to ensure a successful commercial launch in these markets. Full Press Release
Mainz Draws Bullish Views at Cantor Fitzgerald on Potential in Colorectal Cancer Screening
October 25th, 2022 - Cancer test maker Mainz Biomed B.V. (NASDAQ: MYNZ) Cantor Fitzgerald initiated its coverage with an Overweight recommendation noting the company’s prospects in colorectal cancer screening.
Mainz (MYNZ) markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe, and its “European sales provide near-term revenue potential while the company prepares to enter the U.S. market,” the analyst Ross Osborn argues.
The analyst issues positive views on the E.U. and U.S. CRC screening market, estimated at $13B, and notes that the company’s partnership model is likely to improve the adoption of ColoAlert compared to a direct-marketing approach.
Commenting on MYNZ’s valuation disparity with Exact Sciences Corporation (EXAS), its U.S.-based rival in colorectal screening, Osborn argues that the company can close the valuation gap as its sales “volumes accelerate and ColoAlert receives FDA approval.”
The price target at $15 implies over 120% upside to yesterday's closing price but stands lower than the current average price target for MYNZ on Wall Street. Full Cantor Fitzgerald Report
Jones Research Initiated February 9th, 2023 - Staking Its Claim in the Booming CRC Screening Market
Initiating with Buy Rating and $11 PT
Jones Research Report Highlights
"The future: one sample – multiple screenings. In addition to efforts to improve early detection by incorporating mRNA biomarkers into ColoAlert, Mainz is developing PancAlert. PancAlert is a stool-based early detection screening test for pancreatic cancer. While the company is still evaluating the sensitivity of the product and it remains in the early research stage, we are intrigued by the possibilities of screening for multiple cancers using the same stool-sample (i.e., making use of both ColoAlert and PancAlert). Not only could this offer considerable synergies for Mainz, but it could also improve patient outcomes with no increased inconvenience. Theoretically, the company could expand beyond CRC and pancreatic cancer from there and provide early detection of multiple cancers that are amenable to stool-based screening. While we wait for clinical validation of PancAlert, however, we are not including future revenues in our model and leave the product as a source of potential upside for investors."
"Key Catalyst: mRNA feasibility study readout (1H23); 2) begin enrollment in pivotal ReconAAsense trial (mid-2023)."
"Valuation: Our $11 price target is based on risk-adjusted discounted cash flow (DCF) valuation with cash flows forecasted through 2034, along with a 12.5% discount rate and a 0% terminal growth rate. We assume a probability of success of 90% for ColoAlert in the U.S." Full Jones Research Report
MYNZ Statistics as of the Most Recent Quarter (mrq)
Cash on Hand $26M Market Cap $95M Shares Outstanding 14.49M Shares in Float 11M Held by Insiders 23.79% source: Yahoo Finance
The market for MYNZ's ColoAlert is massive and it will not take a very big percentage of market share to catapult this little biotech in to the stratosphere.
📷 Source: MYNZ Corporate Presentation
How Important is Early Detection? IT SAVES LIVES!
📷 Source: MYNZ Corporate Presentation
Should Mainz Biomed goal of combining the Colorectal and Pancreatic tests in to one, we could be looking back on this report as one of our biggest winners ever.
Disclaimer
2023.03.20 15:17 Zottisha You make my life miserable when we are serving in police together? Be properly fined when you break the rules.
This is a long story. English is not my fist language so please forgive typos and grammar. TL;DR at the end.
This story backs to the beginning of the nineties when I (25M at that time) had to serve the mandatory period of one year in the Army in my country. That was a thing everybody disliked, because basically you wasted your time being barely paid some 4 dollars a day without having in return other than some useless basic military training and guard duties and so on.
So, I decided to join a branch of the army which has powers of civilian police, MP and military force, all together, on the aim to at least do something good for the community (and get a decent monthly payment in return). To explain, this means you would be contemporary a police officer, a military police officer, and a soldier. Not so easy to be chosen, but I was more than qualified and I got it.
Take into account that we served in a professional police force, as a sort of auxiliary reserve force that was employed on police and public order duties always together with some professional police officer. Despite our rank was “Auxiliary police”, we had the same power and gears of any other professional police officer, and we had full power to operate alone if it was the case.
Now, the mandatory military service had two choices you could pick: choose to be a basic private, or choose to be a complement lieutenant (if you had the right requisites).
I chose the first because being a lieutenant would mean serving during 18 months instead of twelve. At the time I said no thanks. Let's get rid of it and back home.
Well, many of you know how miserable your life in the military can be if you’re low rank and so unlucky to get the wrong commander. And of course, my platoon was assigned to the most evil, idiotic, dumb*ss 20ish yrs old lieutenant you could imagine. Take into account that we were, for the most part, people who had a good instruction, and smart enough to join a kind of elite force like the one we were in, also because you could postpone the mandatory military duty until you got the university degree. That means that there were a LOT of people with a degree among us. There were lawyers, MDs, architects, and so on. Of course, many of us were well beyond 25 yrs old, so at least a lot more adult and responsible than an entitled child like him.
As in DL (Dumb*ss Lieutenant) opinion, all of us were just some horsesh*t because we were not at his rank level. And he treated us consequently.
Wanna go out the base to see your family when off duty? Nope, permission denied because “you have your shoe sole dirty”. He would ask to check your personal gun and immediately ground you for 15 days because “your gun has not to be given to others no matter what”. Next time, accordingly, you DON’T give him the gun? Well then, “you’re grounded because you disobeyed an order”. Finish your duty in time with good results? Not for him. Go on night shift because you’re lazy and stupid.
…You get the picture. He invented new and smart ways to just…make our life a hell, with no reason except his sadistic satisfaction.
Well, as time goes by, he finishes his duty and gets back to civilian life, where he’s just an entitled jerk with no power of no sort.
And as time goes by, we finish our duty too.
Except 6 of us, who decided to join the force and stay on duty indefinitely.
I was one of them.
So, I stayed in the army and was transferred a couples of months after to our country’s capital. And just went on with my life doing my job until a glorious day, when I was on traffic patrol duty. A black car speeded on a red light in a heavy trafficked urban boulevard with lots of pedestrians, just in front of my eyes.
And who was in charge to decide whether was the case of stopping people or not? You bet it was yours truly.
And who was the driver? You bet it was DL.
To be clear, I didn’t know it was DL, I would have stopped the car anyway because the situation was very dangerous for pedestrians and other drivers. But when I approached the driver’s side to ask for the papers, I recognized him immediately. But he did NOT recognize ME. You know how it works with this kind of entitled jerks, they simply don't care to remember the faces of their slaves.
In my head I said "UUUhhh, dude, you are gonna remember me for a long time after I am done with you".
On a normal voice: “Good morning sir, driver’s license and car papers please”
“Here you are officer”.
Tucked Inside the driver’s license there was a badge of the veteran army police association. Without a blink I gave it back to him saying “this has nothing to do with driving sir, please hold it somewhere else”. He was smirking in a kind of attempt to enhance some “bro code” and saying “I am a retired colleague”. And I responded in a full smile “yes, I perfectly know who you are, you are not retired, you just finished your military service, you served in (name of the town) and I was serving under you, don’t you recognize me?”
If I had hit the guy with a loaded truck couldn’t have hurt him so badly, when he realized the kind of nightmare he was entering, having in front of him a police officer whose life was ruined by him, and having broken traffic rules.
His face turned from smile to despair in less than a second. He knew he was in deep shit, and that he would be fined for red light and speeding.
But what he didn’t know was how deep the shit was. Because you see, he didn’t know that, despite what he said to my face multiple times that “I was just a perfect nobody with no rank”, I was f*cking good at my job. So, what I did was just doing my job properly, nothing more, and I went to check thoroughly EVERY SINGLE issue he could have had in the car.
Speeding? Check, 100 dollars fine. Red light? Check, another 88 dollars fine. No use of safety belt? Check, 95 dollars fine. Dangerous driving in town street? Check, 155 dollars fine. Tires not properly maintained? Check, 45 dollars.
…and so on and on and on and on, until he was begging me to stop, but you know, when he said “I guess I have learned my lesson now”, I told him that there was nothing personal, after all I am just “a perfect nobody with no rank”, so I have just to abide and apply the law. And went on and on and on.
When I finished, a looooong time after, believe me: he WAS finished also.
So I told him “I should just confiscate your car and tow it, with some kind of 2500 more dollars fine, but I am NOT a fucking asshole who takes advantage by his power. Let me just give you the best regards from my fellow platoon mates and show off”.
That night, I don’t know why, I slept very very well, with a smile on my face.
TL;DR I caught a jerk former police officer, who made my life miserable during his service, red-handed breaking traffic rules, and fined him accordingly.
EDIT: typos
submitted by Zottisha to pettyrevenge [link] [comments]
This story backs to the beginning of the nineties when I (25M at that time) had to serve the mandatory period of one year in the Army in my country. That was a thing everybody disliked, because basically you wasted your time being barely paid some 4 dollars a day without having in return other than some useless basic military training and guard duties and so on.
So, I decided to join a branch of the army which has powers of civilian police, MP and military force, all together, on the aim to at least do something good for the community (and get a decent monthly payment in return). To explain, this means you would be contemporary a police officer, a military police officer, and a soldier. Not so easy to be chosen, but I was more than qualified and I got it.
Take into account that we served in a professional police force, as a sort of auxiliary reserve force that was employed on police and public order duties always together with some professional police officer. Despite our rank was “Auxiliary police”, we had the same power and gears of any other professional police officer, and we had full power to operate alone if it was the case.
Now, the mandatory military service had two choices you could pick: choose to be a basic private, or choose to be a complement lieutenant (if you had the right requisites).
I chose the first because being a lieutenant would mean serving during 18 months instead of twelve. At the time I said no thanks. Let's get rid of it and back home.
Well, many of you know how miserable your life in the military can be if you’re low rank and so unlucky to get the wrong commander. And of course, my platoon was assigned to the most evil, idiotic, dumb*ss 20ish yrs old lieutenant you could imagine. Take into account that we were, for the most part, people who had a good instruction, and smart enough to join a kind of elite force like the one we were in, also because you could postpone the mandatory military duty until you got the university degree. That means that there were a LOT of people with a degree among us. There were lawyers, MDs, architects, and so on. Of course, many of us were well beyond 25 yrs old, so at least a lot more adult and responsible than an entitled child like him.
As in DL (Dumb*ss Lieutenant) opinion, all of us were just some horsesh*t because we were not at his rank level. And he treated us consequently.
Wanna go out the base to see your family when off duty? Nope, permission denied because “you have your shoe sole dirty”. He would ask to check your personal gun and immediately ground you for 15 days because “your gun has not to be given to others no matter what”. Next time, accordingly, you DON’T give him the gun? Well then, “you’re grounded because you disobeyed an order”. Finish your duty in time with good results? Not for him. Go on night shift because you’re lazy and stupid.
…You get the picture. He invented new and smart ways to just…make our life a hell, with no reason except his sadistic satisfaction.
Well, as time goes by, he finishes his duty and gets back to civilian life, where he’s just an entitled jerk with no power of no sort.
And as time goes by, we finish our duty too.
Except 6 of us, who decided to join the force and stay on duty indefinitely.
I was one of them.
So, I stayed in the army and was transferred a couples of months after to our country’s capital. And just went on with my life doing my job until a glorious day, when I was on traffic patrol duty. A black car speeded on a red light in a heavy trafficked urban boulevard with lots of pedestrians, just in front of my eyes.
And who was in charge to decide whether was the case of stopping people or not? You bet it was yours truly.
And who was the driver? You bet it was DL.
To be clear, I didn’t know it was DL, I would have stopped the car anyway because the situation was very dangerous for pedestrians and other drivers. But when I approached the driver’s side to ask for the papers, I recognized him immediately. But he did NOT recognize ME. You know how it works with this kind of entitled jerks, they simply don't care to remember the faces of their slaves.
In my head I said "UUUhhh, dude, you are gonna remember me for a long time after I am done with you".
On a normal voice: “Good morning sir, driver’s license and car papers please”
“Here you are officer”.
Tucked Inside the driver’s license there was a badge of the veteran army police association. Without a blink I gave it back to him saying “this has nothing to do with driving sir, please hold it somewhere else”. He was smirking in a kind of attempt to enhance some “bro code” and saying “I am a retired colleague”. And I responded in a full smile “yes, I perfectly know who you are, you are not retired, you just finished your military service, you served in (name of the town) and I was serving under you, don’t you recognize me?”
If I had hit the guy with a loaded truck couldn’t have hurt him so badly, when he realized the kind of nightmare he was entering, having in front of him a police officer whose life was ruined by him, and having broken traffic rules.
His face turned from smile to despair in less than a second. He knew he was in deep shit, and that he would be fined for red light and speeding.
But what he didn’t know was how deep the shit was. Because you see, he didn’t know that, despite what he said to my face multiple times that “I was just a perfect nobody with no rank”, I was f*cking good at my job. So, what I did was just doing my job properly, nothing more, and I went to check thoroughly EVERY SINGLE issue he could have had in the car.
Speeding? Check, 100 dollars fine. Red light? Check, another 88 dollars fine. No use of safety belt? Check, 95 dollars fine. Dangerous driving in town street? Check, 155 dollars fine. Tires not properly maintained? Check, 45 dollars.
…and so on and on and on and on, until he was begging me to stop, but you know, when he said “I guess I have learned my lesson now”, I told him that there was nothing personal, after all I am just “a perfect nobody with no rank”, so I have just to abide and apply the law. And went on and on and on.
When I finished, a looooong time after, believe me: he WAS finished also.
So I told him “I should just confiscate your car and tow it, with some kind of 2500 more dollars fine, but I am NOT a fucking asshole who takes advantage by his power. Let me just give you the best regards from my fellow platoon mates and show off”.
That night, I don’t know why, I slept very very well, with a smile on my face.
TL;DR I caught a jerk former police officer, who made my life miserable during his service, red-handed breaking traffic rules, and fined him accordingly.
EDIT: typos
2023.03.20 15:13 SituationLive4406 MYNZ Multiple Catalysts Ahead
 | Hello everyone and welcome to all our new members, submitted by SituationLive4406 to BroadStreetBets [link] [comments] Today we have a diagnostics biotech company with near-term catalysts, small float, potential chart breakout, great news just released and recent analyst coverage indicating over 120% upside (See Analyst Reports Below). This one has demonstrated the ability to run up fast in recent months! Note\* Mainz Biomed's ColoAlert test is currently approved and commercially available in Europe and select International markets. Sales, commercial partnerships and marketing activities are starting to ramp up NOW! This leaves an open door for multiple near-term catalysts. Mainz Biomed B.V. (NASDAQ: MYNZ) a molecular genetics diagnostic company specializing in the early detection of cancer. The company operates a clinical diagnostic laboratory and generates the majority of its revenue from in-licensed CE-IVD marked stool-based colorectal cancer (CRC) detection test ColoAlert. While working to expand ColoAlert sales in European markets, Mainz is developing potential improvements for a second generation product. While the first generation of ColoAlert combines the fecal immunochemical test (FIT) with multiple DNA mutation markers to detect early stage CRC, the company is investigating the addition of novel mRNA biomarkers that may be able to detect pre-cancerous polyps with best-in-class potential. Clinical data from patients treated at the Hamamatsu University School of Medicine (Japan) and the Centre Hospitalier Universitaire de Sherbrooke (CHUS; Canada) indicate that the mRNA biomarkers being tested are able to achieve high sensitivity and specificity (published results here) and Mainz is expected to release its own feasibility study results in 1H23. Following Our Last Report, Mainz Biomed in a Very Smart Move Acquired the Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program Excerpt from this article: “This is an important value generation milestone for us as we continue executing our commercial strategy and product development plan to ultimately bring to market the gold-standard CRC self-administered diagnostic test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Securing complete IP ownership is integral to our growth strategy as it streamlines administration, reduces per-test expenses, and provides us the opportunity to ramp-up corporate development activities,” added Baechler. FULL ARTICLE Recent News, Another Catalyst Announced Last Week Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany Labor Staber to actively market and sell ColoAlert to its physician and patient network. BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber & Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany. FULL ARTICLE Mainz Biomed Enters Commercial Partnerships for ColoAlert with two Independent Laboratories News Issued Feb. 15, 2023 - Mainz Biomed (NASDAQ: MYNZ) on Wednesday has formed commercial partnerships for ColoAlert with Marylebone Laboratory and Instituto de Microecologia, two leading independent laboratories covering England and Spain. Mainz (MYNZ) markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe and being commercialized in select international markets via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. In the forthcoming weeks, Mainz Biomed will work with both partners to complete the necessary technical and co-marketing activities to ensure a successful commercial launch in these markets. Full Press Release Mainz Draws Bullish Views at Cantor Fitzgerald on Potential in Colorectal Cancer Screening October 25th, 2022 - Cancer test maker Mainz Biomed B.V. (NASDAQ: MYNZ) Cantor Fitzgerald initiated its coverage with an Overweight recommendation noting the company’s prospects in colorectal cancer screening. Mainz (MYNZ) markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe, and its “European sales provide near-term revenue potential while the company prepares to enter the U.S. market,” the analyst Ross Osborn argues. The analyst issues positive views on the E.U. and U.S. CRC screening market, estimated at $13B, and notes that the company’s partnership model is likely to improve the adoption of ColoAlert compared to a direct-marketing approach. Commenting on MYNZ’s valuation disparity with Exact Sciences Corporation (EXAS), its U.S.-based rival in colorectal screening, Osborn argues that the company can close the valuation gap as its sales “volumes accelerate and ColoAlert receives FDA approval.” The price target at $15 implies over 120% upside to yesterday's closing price but stands lower than the current average price target for MYNZ on Wall Street. Full Cantor Fitzgerald Report Jones Research Initiated February 9th, 2023 - Staking Its Claim in the Booming CRC Screening Market Initiating with Buy Rating and $11 PT Jones Research Report Highlights "The future: one sample – multiple screenings. In addition to efforts to improve early detection by incorporating mRNA biomarkers into ColoAlert, Mainz is developing PancAlert. PancAlert is a stool-based early detection screening test for pancreatic cancer. While the company is still evaluating the sensitivity of the product and it remains in the early research stage, we are intrigued by the possibilities of screening for multiple cancers using the same stool-sample (i.e., making use of both ColoAlert and PancAlert). Not only could this offer considerable synergies for Mainz, but it could also improve patient outcomes with no increased inconvenience. Theoretically, the company could expand beyond CRC and pancreatic cancer from there and provide early detection of multiple cancers that are amenable to stool-based screening. While we wait for clinical validation of PancAlert, however, we are not including future revenues in our model and leave the product as a source of potential upside for investors." "Key Catalyst: mRNA feasibility study readout (1H23); 2) begin enrollment in pivotal ReconAAsense trial (mid-2023)." "Valuation: Our $11 price target is based on risk-adjusted discounted cash flow (DCF) valuation with cash flows forecasted through 2034, along with a 12.5% discount rate and a 0% terminal growth rate. We assume a probability of success of 90% for ColoAlert in the U.S."Full Jones Research Report MYNZ Statistics as of the Most Recent Quarter (mrq) Cash on Hand $26MMarket Cap $95MShares Outstanding 14.49MShares in Float 11MHeld by Insiders 23.79%source: Yahoo Finance The market for MYNZ's ColoAlert is massive and it will not take a very big percentage of market share to catapult this little biotech in to the stratosphere. https://preview.redd.it/mj38svpqnwoa1.png?width=1516&format=png&auto=webp&s=447bb64f2ad14cce2a9fdf2cee99af064e86d328 Source: MYNZ Corporate Presentation How Important is Early Detection? IT SAVES LIVES! https://preview.redd.it/0uuermirnwoa1.png?width=1179&format=png&auto=webp&s=a6a1a4ffcf9be4ad8886aa52eeb41104b9a55721 Source: MYNZ Corporate Presentation Should Mainz Biomed goal of combining the Colorectal and Pancreatic tests in to one, we could be looking back on this report as one of our biggest winners ever. Disclaimer |
2023.03.20 15:10 AutoModerator [Get] Simpler Trading – Bulletproof Butterflies 2.0 Elite by Bruce Marshall Download course on Genkicourses.com
| | Get the course here: https://www.genkicourses.com/product/simpler-trading-bulletproof-butterflies-2-0-elite/ submitted by AutoModerator to G3nki_Courses_ [link] [comments] [Get] Simpler Trading – Bulletproof Butterflies 2.0 Elite by Bruce Marshall Download course on Genkicourses.com https://preview.redd.it/3qw652ifeqoa1.jpg?width=1280&format=pjpg&auto=webp&s=236c11fdf4ac5968bb61e3b75145f0e84bbd229f BULLETPROOF BUTTERFLIES (ELITE PACKAGE) – SIMPLER TRADING BY BRUCE MARSHALLBeat Volatile Markets… With ‘Bulletproof Butterflies’ Use this Weekly Options Strategy to Boost Short-Term GainsWHO IS BRUCE MARSHALL?Director of Options and Income TradingBruce is a devoted mentor here at Simpler. After spending many years on Wall Street managing institutional and retail accounts, we’re lucky to have him trading in several memberships of ours. In addition to the Options Chatroom, he has his own service called Bruce’s Income Accumulation System (BIAS), where he focuses heavily on some of his favorite strategies. If you’re looking to improve you risk/reward ratio, or you’re not able to devote large amounts of time sitting watching the charts, Bruce may be just the trader you’re looking for. As his trades develop over a longer span of time — sometimes even months at a time. First and foremost though, if you want to know more about the Greeks, there’s no one better than Bruce. DO YOU STRUGGLE WITH GENERATING CONSISTENT INCOME THROUGH CRAZY MARKET UPS AND DOWNS?With all that’s happening in the world, the market once again kicked into “crazy” mode. You’ll have to adjust your trading strategy, or watch your account balance plummet with no hope of recovery.That’s why Bruce Marshall developed a new twist to a reliable short-term setup — so you can turn these swings into weekly income! The goal is to set the trade, let it work, and then come back a short time later and take the gains. With the “Bulletproof Butterflies” setup we were in and out of the trade in four hours with $700 profit. This is right in line with a target of making $250 – $500 in consistent weekly income. Just imagine averaging one trade like this each week. That kind of steady cash flow can really add up. THERE’S SERIOUS MONEY IN THE MARKET… WITH THE RIGHT TOOLSWhat’s great about “Bulletproof Butterflies” is that you can profit even if the market doesn’t move as you expect. Plus, you can defend these positions easily if need be…Bruce poured his 30+ years of experience as a full-time trader into this strategy. He made a name for himself managing 100-plus million-dollar funds on Wall Street. “Bulletproof Butterflies” is his answer to repeated questions from new and seasoned traders wanting to develop consistent income. When you trade an uncertain market, you know a nice upward trend won’t last — maybe not even a few hours. So the question becomes how to make consistent money? Bruce sticks to what has worked for years… a time-tested butterfly strategy for any trend in the market. “Bulletproof Butterflies” are great because they’re meant to be flexible. So you don’t have to be “dead on” correct to come out on top! You can trade them small or stack them, and they’re designed for short-term cash flow. There’s plenty of money to be made in this market, you just need the right tools. In Bruce’s income class, you will discover: How to “dial” up or down your risk over the life of the trade. The complete details of this low-maintenance setup. Learn a simple weekly strategy that works over and over in bullish or bearish conditions. How to instantly tell a good setup from a bad one and properly calculate your risk vs. reward. Learn the pros and cons of trading weeklies. What to do when your trade gets into trouble. And a whole lot more… |
2023.03.20 15:04 Neelycounseling Best Counselors Services Near Me
Learn more about the best counselor services near me and connect with a therapist today. ... Learn more about Neely Counseling which provides convenient, affordable online therapy when need it from a licensed, board-accredited therapist.
submitted by Neelycounseling to u/Neelycounseling [link] [comments]
2023.03.20 14:15 SchlesingerMindy323 [HIRING] 25 Jobs in DE Hiring Now!
2023.03.20 14:10 AutoModerator [Get] Simpler Trading – Bulletproof Butterflies 2.0 Elite by Bruce Marshall Download course on Genkicourses.com
| | Get the course here: https://www.genkicourses.com/product/simpler-trading-bulletproof-butterflies-2-0-elite/ submitted by AutoModerator to G3nki_Courses_ [link] [comments] [Get] Simpler Trading – Bulletproof Butterflies 2.0 Elite by Bruce Marshall Download course on Genkicourses.com https://preview.redd.it/3qw652ifeqoa1.jpg?width=1280&format=pjpg&auto=webp&s=236c11fdf4ac5968bb61e3b75145f0e84bbd229f BULLETPROOF BUTTERFLIES (ELITE PACKAGE) – SIMPLER TRADING BY BRUCE MARSHALLBeat Volatile Markets… With ‘Bulletproof Butterflies’ Use this Weekly Options Strategy to Boost Short-Term GainsWHO IS BRUCE MARSHALL?Director of Options and Income TradingBruce is a devoted mentor here at Simpler. After spending many years on Wall Street managing institutional and retail accounts, we’re lucky to have him trading in several memberships of ours. In addition to the Options Chatroom, he has his own service called Bruce’s Income Accumulation System (BIAS), where he focuses heavily on some of his favorite strategies. If you’re looking to improve you risk/reward ratio, or you’re not able to devote large amounts of time sitting watching the charts, Bruce may be just the trader you’re looking for. As his trades develop over a longer span of time — sometimes even months at a time. First and foremost though, if you want to know more about the Greeks, there’s no one better than Bruce. DO YOU STRUGGLE WITH GENERATING CONSISTENT INCOME THROUGH CRAZY MARKET UPS AND DOWNS?With all that’s happening in the world, the market once again kicked into “crazy” mode. You’ll have to adjust your trading strategy, or watch your account balance plummet with no hope of recovery.That’s why Bruce Marshall developed a new twist to a reliable short-term setup — so you can turn these swings into weekly income! The goal is to set the trade, let it work, and then come back a short time later and take the gains. With the “Bulletproof Butterflies” setup we were in and out of the trade in four hours with $700 profit. This is right in line with a target of making $250 – $500 in consistent weekly income. Just imagine averaging one trade like this each week. That kind of steady cash flow can really add up. THERE’S SERIOUS MONEY IN THE MARKET… WITH THE RIGHT TOOLSWhat’s great about “Bulletproof Butterflies” is that you can profit even if the market doesn’t move as you expect. Plus, you can defend these positions easily if need be…Bruce poured his 30+ years of experience as a full-time trader into this strategy. He made a name for himself managing 100-plus million-dollar funds on Wall Street. “Bulletproof Butterflies” is his answer to repeated questions from new and seasoned traders wanting to develop consistent income. When you trade an uncertain market, you know a nice upward trend won’t last — maybe not even a few hours. So the question becomes how to make consistent money? Bruce sticks to what has worked for years… a time-tested butterfly strategy for any trend in the market. “Bulletproof Butterflies” are great because they’re meant to be flexible. So you don’t have to be “dead on” correct to come out on top! You can trade them small or stack them, and they’re designed for short-term cash flow. There’s plenty of money to be made in this market, you just need the right tools. In Bruce’s income class, you will discover: How to “dial” up or down your risk over the life of the trade. The complete details of this low-maintenance setup. Learn a simple weekly strategy that works over and over in bullish or bearish conditions. How to instantly tell a good setup from a bad one and properly calculate your risk vs. reward. Learn the pros and cons of trading weeklies. What to do when your trade gets into trouble. And a whole lot more… |
2023.03.20 14:05 null_pharaoh Impulse eating/spending on Elvanse
Hey everyone, curious if this is a common experience
I've been on Elvanse since January. starting on 30mg and now up to 70mg. For the first month or two I was excellent at suppressing impulsive urges around food/spending etc, but lately, it's gotten a bit bad again.
Don't get me wrong, it's still a lot better than before - I'm not ordering takeaway every day now, and I'm much better at pulling my thoughts away from impulsive retail therapy. But sometimes, it's hard to avoid urges for things like chocolate and ice cream. Appetite suppression is still working fine oddly enough.
I know the pill's not a magic cure by any means and this is all likely habit based since I've probably got binge eating disorder (my old-local NHS services wouldn't assess me for it for budget reasons apparently) but I don't know if there should be a clearer mental benefit there like there was at the start?
Would also be curious to hear some tips from others really, thank you!
submitted by null_pharaoh to ADHDUK [link] [comments]
I've been on Elvanse since January. starting on 30mg and now up to 70mg. For the first month or two I was excellent at suppressing impulsive urges around food/spending etc, but lately, it's gotten a bit bad again.
Don't get me wrong, it's still a lot better than before - I'm not ordering takeaway every day now, and I'm much better at pulling my thoughts away from impulsive retail therapy. But sometimes, it's hard to avoid urges for things like chocolate and ice cream. Appetite suppression is still working fine oddly enough.
I know the pill's not a magic cure by any means and this is all likely habit based since I've probably got binge eating disorder (my old-local NHS services wouldn't assess me for it for budget reasons apparently) but I don't know if there should be a clearer mental benefit there like there was at the start?
Would also be curious to hear some tips from others really, thank you!
2023.03.20 14:00 Dangerous-Bag-7327 [HIRING] 21 Jobs in Chicago Hiring Now!
2023.03.20 13:57 Final-Reaction2032 These agencies are crap.
First time teletherapist here...9th year as a school SLP.
These agencies are fucking worthless.
I had to sort through all of the virtual SLP options out there in the world tirelessly searching for something W2 with benefits that would compensate for indirect service time. The schools are just too much paperwork and too many unpaid holidays to work for no compensation on indirect time or be jerked into a low hourly rate.
Finally found something that fit the bill for all of the above only to find out...heyyyyy....first 30 days of employment I have an initial that I'm case managing for-no training on IEP or billing software, no platform other than Google Meets, I can't see/hear all my kids in a group because they're huddled around a laptop or sitting 5 feet away from the laptop to catch them in the frame. I'm completely blind going into the eval and the district and the agency bicker like squawking chickens over whose responsibility it is to train me in the district software..meanwhile time is ticking on time sensitive documents.
If this is what it's like with a small, locally owned and operated therapy agency, I can't imagine how bad going with a national therapy staffing company could be.
This profession has really gone down the shitter. I used to work for such a wonderful, small, local therapy company that took such great pride in what they did but we had to close our doors because we could not remain marketplace competitive. Perhaps 40 years ago when my old agency first opened things were different and services made sense. Now, this is just a gross clearinghouse of mismanaged contracts and fraud/waste.
submitted by Final-Reaction2032 to slp [link] [comments]
These agencies are fucking worthless.
I had to sort through all of the virtual SLP options out there in the world tirelessly searching for something W2 with benefits that would compensate for indirect service time. The schools are just too much paperwork and too many unpaid holidays to work for no compensation on indirect time or be jerked into a low hourly rate.
Finally found something that fit the bill for all of the above only to find out...heyyyyy....first 30 days of employment I have an initial that I'm case managing for-no training on IEP or billing software, no platform other than Google Meets, I can't see/hear all my kids in a group because they're huddled around a laptop or sitting 5 feet away from the laptop to catch them in the frame. I'm completely blind going into the eval and the district and the agency bicker like squawking chickens over whose responsibility it is to train me in the district software..meanwhile time is ticking on time sensitive documents.
If this is what it's like with a small, locally owned and operated therapy agency, I can't imagine how bad going with a national therapy staffing company could be.
This profession has really gone down the shitter. I used to work for such a wonderful, small, local therapy company that took such great pride in what they did but we had to close our doors because we could not remain marketplace competitive. Perhaps 40 years ago when my old agency first opened things were different and services made sense. Now, this is just a gross clearinghouse of mismanaged contracts and fraud/waste.
2023.03.20 13:20 drmagotch Sleep Apnea Treatment in Livingston, NJ
 | Sleep apnea is a common sleep disorder that affects millions of people worldwide. Loking for sleep apnea treatment in livingston nj ? Meet, Joseph A. Magotch, DDS, PA, our Livingston cosmetic dentist is committed to your individual attention and strives to provide personalized oral health care tailored for your unique dental needs and goals. We work hard to create the ultimate stress-free and comfortable dental experience. submitted by drmagotch to u/drmagotch [link] [comments] Learn More - https://drmagotch.com/services/sleep-apnea/ https://preview.redd.it/y6tew0nozvoa1.png?width=800&format=png&auto=webp&s=75a8c68fd36cf09dcbe282d1f7aae3521d5476cf |